Abiraterone
(asked on 17th October 2025) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the NICE guidance on abiraterone produced in 2021 was based on abiraterone's cost in generic form.
The National Institute for Health and Care Excellence’s (NICE) published guidance on abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer, which has the reference code TA721, was developed before the patent for abiraterone expired and was therefore based on the cost of the branded medicine.
NICE is now re-evaluating abiraterone, both the originator and the generics, for the treatment of newly diagnosed high-risk hormone-sensitive metastatic prostate cancer and currently expects to publish the final guidance on 19 November 2025. The progress of this guidance can be followed at the following link: